Arcturus Therapeutics’ biggest vaccine partner has soured on their relationship, and that fallout could unexpectedly free the company to team up with new pharma giants. The story digs into why this breakup matters, what new partners like Sanofi or BioNTech might want from Arcturus’ RNA platform, and what could still derail the upside.Read more
Arcturus builds RNA-based vaccines and treatments, but its income from past deals is fading while its next products still face long development and approval paths. With only a few key programs carrying the story, setbacks, competition, or slower partner payments could leave the company burning cash for longer than investors expect.Read more
Key Takeaways Unique mRNA platform enables rapid market expansion and premium positioning in vaccines, with strong potential for high-margin, recurring revenues and first-mover advantages. Operational efficiency and breakthrough pipeline support sustainable growth, while industry trends drive significant partnering and shareholder value-creation opportunities.Read more
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
